AtriCure (NSDQ:ATRC) said today it launched the CryoForm cryoablation probe for use in cardiac ablation procedures, such as atrial fibrillation.
The CryoForm includes the ability to remove heat and actively defrost, which allows the operator to safely detach the device while maintaining internal tissue’s frozen state, the West Chester, Ohio-based company said.
“We are excited to announce the launch of the CryoForm probe. This builds off of one of our company’s core competencies in cryoablation, and offers our customers another option when performing surgical ablation by allowing for easier manipulation and application of the device. We have listened to our customers’ requests for a significantly more flexible probe that doesn’t compromise on the core strengths and features they value most,” CEO Mike Carrel said in prepared remarks.
AtriCure said the device is “intended to address the trend towards minimally invasive techniques in cardiac surgery,” and to be used in conjunction with other cardiac therapies, such as mitral and aortic valve repair.
“The CryoForm probe works well in MI-MVR procedures and allows me to easily shape and position the probe inside the LA using endoscopic instruments. The probe is a great addition to the cryoICE family that I can rely on for fully transmural lesions,” Dr. Nicolas Doll of Stuttgart, Germany’s Sana Herzchirugie said in a press release.
The CryoForm device has received CE Mark approval in the European union and has regulatory clearance pending with the FDA, the company said.
